FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms

Key facts

Sponsor

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Intervention

FCN-338 + Azacitidine(combination_product)

Enrollment

47 target

Eligibility

18 years · All sexes

Timeline

2023 – 2026

Study locations (1)

• Union hospital tongjimedical college huzhong university of science and technology, Wuhan, China

Collaborators

Beijing Fosun Pharmaceutical Technology Development Co., Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Inherited acute myeloid leukemia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT06782542
  Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy
  Justin Watts, MD
• RECRUITINGPHASE2NCT06557421
  De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients
  Institut Paoli-Calmettes
• RECRUITINGPHASE1NCT07130695
  Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation
  Virginia Commonwealth University
• RECRUITINGPHASE1NCT07320235
  Imetelstat Combinations in Relapsed AML
  Douglas Tremblay
• RECRUITINGPHASE2NCT06904482
  Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
  Case Comprehensive Cancer Center
• RECRUITINGNCT07163728
  Leptin: A Marker for AML Chemo-Sensitivity
  Fujian Medical University Union Hospital
• RECRUITINGNANCT06697600
  A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
  University of Rochester
• RECRUITINGPHASE2, PHASE3NCT06972641
  Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation
  Ruijin Hospital

See all trials for Inherited acute myeloid leukemia →